Amneal Pharmaceuticals, Inc. AMRX Specialty — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — goodwill?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — goodwill of $366.31M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — goodwill changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — goodwill decreased by 0.0% year-over-year, from $366.31M to $366.31M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — goodwill?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — goodwill has grown at a 7.6% compound annual growth rate (CAGR), from $1.09B to $1.47B.
- What does specialty — goodwill mean?
- Represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations specifically allocated to the specialty pharmaceutical segment. This intangible asset reflects the premium paid for brand equity, market position, and future growth potential within the specialty medicine portfolio.